Skip to contentB
BridgeBio Pharma, Inc.
B
BBIOBridgeBio Pharma, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$5.88M$5.88Mderived+237.1% vs Q4 2023 Net Income-$259.80M-$259.80MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BridgeBio Pharma, Inc. · CIK 1743881 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$226,027,000N/M Operating Cash Flowderived-$195,326,000N/M Free Cash Flowderived-$195,373,000N/M Margins · derivedOperating margin-3842.7%+6324.4 pt vs Q4 2023
Net margin-4416.9%+4768.1 pt vs Q4 2023
ended Dec 31, 2024 · filed Feb 20, 2025 · 51 d after period end